http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1137425-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba090c867801ab7bccb082f1b694ad25
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D219-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D219-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D219-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D219-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D265-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D265-18
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D265-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D219-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D265-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D219-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D219-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D219-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B02C18-06
filingDate 1966-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1968-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber GB-1137425-A
titleOfInvention Phenoxyazinyl and acridanyl aminocyclopropanes
abstract 1,137,425. Phenoxazine and acridan derivatives. SMITH KLINE & FRENCH LABORATORIES. 22 July, 1966 [23 July, 1965 (2)], No. 33211/66. Heading C2C. Novel compounds of Formula I, in which Y is oxygen or =CR 3 R 4 , R 3 and R 4 being hydrogen or C 1-3 alkyl, R is hydrogen, chlorine, bromine, trifluoromethyl, methyl, methoxy or methylthio, each of m and n is 0 or 1, each of R 1 and R 2 is hydrogen or C 1-3 alkyl or R 1 and R 2 , together with the nitrogen atom to which they are attached, represent a 1-pyrrolidinyl, piperidino or 4-methyl-1-piperazinyl ring, and their pharmaceutically acceptable acid addition salts are prepared as follows: (a) the compounds in which m is 0 and n is 1 are prepared by reacting a compound of Formula II with a compound of Formula III and reducing the resulting amide of Formula IV; the compounds where m and n are 1 and -NR 1 R 2 represents a tertiary amino group are prepared by reacting a compound of Formula II with an active ester derivative of an aminocyclopropyl carbinol of Formula V, in which -NR 1 R 2 represents a tertiary amino group; (c) the compounds where n is 1 are prepared by reacting an acid of Formula VI with a C 1-3 alkyl haloformate to give the corresponding cyclopropyl mixed anhydride and then treating this with an amine of formula HNR 1 R 2 to give the cyclopropane-carboxamide and reducing this to the aminomethyl-cyclopropane; (d) the compounds in which n is 0 are prepared by reacting an acid of Formula VI with a C 1-3 alkyl haloformate and then with sodium azide to give the cyclopropyl carboxylic acid azide, thermally decomposing this to give the corresponding isocyanate, treating this with (i) a hydrolysing medium to give the primary aminocyclopropane, or (ii) a C 1-2 alkyl magnesium halide or C 1-3 alkanol to give an N-C 2-3 acyl- or N - C 2-4 carbalkoxy - aminocyclopropane, and either reducing this directly to give an N-C 2-3 alkylaminocyclopropane or N - methylaminocyclopropane, respectively, or further reacting it with a C 1-3 alkyl iodide to give an N-C 1-3 alkyl- N-C 2-3 acyl or N-C 1-3 alkyl-N-C 2-4 carbalkoxyaminocyclopropane, respectively, and reducing this to give an N-C 1-3 alkyl-N-C 2-3 alkylaminocyclopropane or N-C 1-3 alkyl-N-methylaminocyclopropane, respectively; (e) the compounds where -NR 1 R 2 represents a heterocyclic ring are prepared from the corresponding primary amines by reacting them with 1,4-dibromobutane, 1,5-dibromopentane or methyl bis-(#- chloroethyl) amine to give the 1-pyrrolidinyl, piperidino and 4-methyl-1-piperazinyl compounds respectively. The compounds are obtained in the cis and/or trans form depending on the method of preparation. The acid addition salts are prepared by known methods. Cyclopropane-carboxylic acids of Formula VI are prepared by reacting a compound of Formula II with ethyl 2-bromo- or 2-bromomethyl - cyclopropane - carboxylate and hydrolysing the resulting ester. The cis- and transacids of Formula VI in which m is 0 and n is 1, are also prepared by reacting an appropriate 10-vinylphenoxazine or 10-vinyl-acridan with ethyl diazoacetate to give a mixture of cis- and trans - heterocyclic cyclopropane carboxylates, selectively hydrolysing this mixture to give the trans-acid and unhydrolysed cis-ester, and hydrolysing the cis-ester with excess alkali to give the cis-acid. 2 - Chloro - 10 - vinyl - phenoxazine is prepared by reacting 2-chlorophenoxazine with diethylaminoethyl chloride hydrochloride to give 2 - chloro - 10 - (2 - dimethylaminoethyl)- phenoxazine, reacting this with methyl iodide to form the corresponding methiodide and then subjecting this to Hoffman degradation. Pharmaceutical compositions having antidepressant activity, for oral or parenteral administration, comprise one of the novel compounds together with a carrier.
priorityDate 1965-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID75646
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID642351
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559213
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457311044
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416051366
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410441854
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID431996470
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393705
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425193155
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15655
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID977
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394314
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409110655
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12192
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559516
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414862870
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154182397
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13363
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24408
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID432078342
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421120963
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID431928748
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410506103
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID432132393
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID783
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154094093
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154157767
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393787
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID138115472
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451936144
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409443016
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7106
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457560897
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154343890
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426228520
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID93238
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415792846
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414862846
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419523291
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8100
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452268449
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID67278
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556587
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57049015
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6328
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419568690
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393806
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID105034
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16723172
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8056
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID260
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID69828
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394313
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID80376
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11029756
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419596966
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414312058
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416047771
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457572950
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410528176
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394295
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10632580
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID33557
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421142634
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID432431340
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45489680

Total number of triples: 89.